Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
In a challenging market environment, Quidel Corporation (NASDAQ:QDEL) stock has touched a 52-week low, reaching a price level of $25.00 USD. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with analysts setting price targets ranging from $38 to $60. This significant downturn reflects a broader trend for the diagnostic healthcare solutions provider, which has seen its stock price decline by -32.06% over the past year. While the company currently faces profitability challenges, InvestingPro analysis indicates potential improvement ahead, with net income expected to grow this year. Investors are closely monitoring the company’s performance as it navigates through the headwinds affecting the healthcare sector, with hopes for a strategic pivot that could revitalize its market position. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis for QDEL through the Pro Research Report, available with your subscription.
In other recent news, Quidel Corporation reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with an EPS of $0.63, compared to the forecasted $0.58. Revenue also exceeded predictions, reaching $708 million against the anticipated $698.09 million. The company provided positive guidance for 2025, projecting total revenue between $2.6 billion and $2.81 billion, with an adjusted EBITDA margin target of 22%. Additionally, Quidel is focusing on cost savings, aiming for $50 million in the first half of 2025. In another development, QuidelOrtho Corporation launched the QuidelOrtho Results Manager System, a new informatics platform designed to enhance laboratory operations and patient care. This system aims to optimize clinical decision-making with features like auto-verification and real-time quality monitoring. Quidel continues to focus on innovation, with ongoing clinical trials and product developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.